Market Place
Sourcing Support
Merck Sharp And Dohme’s Idvynso Receives Approval in US
20 Apr 2026 //
FDA
Merck`s Biologics Keytruda Receives Suppl Approval in US
24 Jul 2025 //
FDA
Merck`s Biologics Keytruda Receives Suppl Approval in US
22 May 2025 //
FDA
Merck`s Capvaxive Receives Approval in Europe
24 Mar 2025 //
EMA
Merck`s Biologic Keytruda Receives Approval in US
19 Mar 2025 //
FDA
Merck`s Biologic Keytruda Receives Suppl Approval in US
11 Dec 2024 //
FDA
Merck Sharp`s Biologic Keytruda Receives Suppl Approval in US
20 Nov 2024 //
FDA
Merck Sharp Dohme Biologic Pembrolizumab Receives Suppl Approval in US
17 Jun 2024 //
FDA
Merck Sharp Dohme Biologic Pembrolizumab Receives Approval in US
07 Jun 2024 //
FDA
Merck`s Biologic Winrevair (sotatercept) Receives Approval in U.S
27 Mar 2024 //
FDA
Merck`s Biologic Keytruda (pembrolizumab) Receives Approval in the U.S.
12 Jan 2024 //
FDA
Merck`s Biologic Keytruda (pembrolizumab) Receives Approval in the U.S.
07 Nov 2023 //
FDA
Merck`s Lyfnua (gefapixant) Receives Approval in Europe
10 Oct 2023 //
EMA
Merck`s Biologic Keytruda (pembrolizumab) Receives Approval in the U.S
14 Aug 2023 //
FDA
Merck`s Biologic Keytruda(Pembrolizumab) Receives Approval in the U.S.
03 Apr 2023 //
FDA
Merck`s Biologic Keytruda (Pembrolizumab) Receives Approval in the U.S.
26 Jan 2023 //
FDA
Merck` Biologic Keytruda (Pembrolizumab) Receives Approval in the U.S.
16 Dec 2022 //
FDA
Merck & Co. Inc.Generic Keytruda (pembrolizumab)Receives Approval in US
05 Aug 2022 //
FDA
Merck & Co. Inc.Generic Keytruda (pembrolizumab)Receives Approval in US
21 Jun 2022 //
FDA
Merck Europe B.V. Tepmetko(tepotinib) Receives Approval in Europe
05 May 2022 //
EMA
Merck `s Keytruda (pembrolizumab) Receives Supplemental Approval In US
15 Oct 2021 //
FDA
Merck`s Biologic Pembrolizumab Receives Supplemental Approval in the US
31 Aug 2021 //
FDA
Orange`s Generic Erythromycin Receives Approval in USA
28 Jun 2021 //
FDA
MSD`s Keytruda (pembrolizumab)Receives Supplemental Approval In U.S
06 May 2021 //
FDA
Merck Sharp Dohme`s Keytruda (pembrolizumab) Receives Approval In US
24 Mar 2021 //
FDA
Merck Sharp Dohme`s Biological Pembrolizumab Receives Approval In US
06 Oct 2020 //
FDA
Merck Sharp`s Keytruda (Pembrolizumab) Receives Supplemental Approval In US
17 Jun 2020 //
FDA
Merk`s KEYTRUDA (pembrolizumab) Receives Supplemental Approval In US
08 Jan 2020 //
FDA
Merck Sharp`s Keytruda (Pembrolizumab) Receives Supplemental Approval In US
20 Sep 2019 //
FDA
Merck`s Keytruda (Pembrolizumab) Receives Supplemental Approval in US
19 Feb 2019 //
FDA
Merck Sharp Dohme`s Biological Pembrolizumab Receives Approval in US
09 Nov 2018 //
FDA
Merck`s Biological Pembrolizumab Receives Approval in US
31 Oct 2018 //
FDA
Merck`s Keytruda (pembrolizumab) Receives Approval in EU
10 Oct 2018 //
EMA
Merck`s Steglatro (ertugliflozin) Receives Approval In Europe
06 Apr 2018 //
EMA
Merck`s Steglujan (ertugliflozin / sitagliptin) Receives Approval In Europe
05 Apr 2018 //
EMA
MSD`s Ilumya (tildrakizumab) Receives Supplemental Approval In US
23 Mar 2018 //
FDA
Merck Sharp & Dohme`s Prevymis (letermovir) Receives Approval In Europe
19 Jan 2018 //
EMA
Merck Serono Europe`s Mavenclad cladribine Receives Approval In Europe
09 Sep 2017 //
EMA
Merck’s Keytruda Pembrolizumab Supplemetal Receives Approval In US
31 Jul 2017 //
FDA
Merck Sharp Dohme Generic Pembrolizumab Receives Approval In US
13 Mar 2017 //
FDA
Merck Sharp & Dohme Limited Gets EU Nod For Zinplava ( Bezlotoxumab)
08 Mar 2017 //
EMA
Merck Sharp & Dohme Gets EU Recommendation for Zinplava
23 Nov 2016 //
EMA
Merck`s Zinplava (Bezlotoxumab) Receives Approval In US
22 Oct 2016 //
FDA
Merck`s Keytruda (Pembrolizumab) Receives Supplemental Approval in US
22 Oct 2016 //
FDA
